- Home
- Products
SARCLISA® (isatuximab-irfc)
SARCLISA® (isatuximab-irfc)
- Medicine Name: Sarclisa
- Generic Name: Isatuximab-irfc
- Dosage Form & Strength: Injection – 100 mg/5 mL (20 mg/mL) and 500 mg/25 mL (20 mg/mL)
- Manufactured By: Sanofi
Sarclisa (Isatuximab-irfc) is a CD38-directed cytolytic monoclonal antibody used in combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least two prior therapies, including:
- Lenalidomide
- A proteasome inhibitor
Recommended Dosage:
10 mg/kg as an intravenous infusion weekly for the first 4 weeks (Cycle 1), followed by every 2 weeks from Cycle 2 onwards (28-day cycles). Treatment is continued until disease progression or unacceptable toxicity. If a dose is missed, administer it as soon as possible and resume the treatment schedule.
- Contraindicated in patients with severe hypersensitivity to Isatuximab or any of its excipients.
- Risk of infusion-related reactions. Premedicate with acetaminophen, antihistamines, corticosteroids, and H2 blockers before each infusion.
- Neutropenia is common. Monitor complete blood counts regularly. Use antimicrobial prophylaxis as needed and evaluate patients for signs of infection.
- Monitor vital signs closely during infusion. For Grade 1/2 reactions, interrupt infusion and provide appropriate care.
- Sarclisa may cause fetal harm and fetal immune suppression. Advise women of reproductive potential to use effective contraception during treatment and for 5 months after the last dose.
- Second primary malignancies have been reported. Long-term monitoring is advised following IMWG guidelines
To import Sarclisa (Isatuximab-irfc) through GlobalRareMeds, the following documents are required:
- Valid prescription from a licensed medical oncologist
- Patient’s diagnostic reports confirming multiple myeloma diagnosis
- Government-issued photo ID of the patient
Order Confirmation:
Orders will be confirmed only after receipt and verification of the prescription and, if necessary, an import permit.
GlobalRareMeds sources Sarclisa from licensed global suppliers across the USA, Canada, Europe, and Australia.
Orders are processed via our fulfillment center in Ambernath, Thane District, with compliance to all cold chain and regulatory standards.
We offer delivery across:
- India – Including cities like Mumbai, Delhi, Hyderabad, Chennai, Bangalore, Kolkata, Pune, Ahmedabad, and more
- International destinations, subject to applicable import laws
📧 Email: info@globalraremeds.com
📞 Call/WhatsApp: +91-99675 15602
Q. What is the generic name of Sarclisa?
A. The generic name is Isatuximab-irfc.
Q. Who manufactures Sarclisa?
A. Sarclisa is manufactured by Sanofi.
Q. Is Sarclisa approved by the FDA?
A. Yes, Sarclisa received FDA approval on March 31, 2021.
Q. What does Sarclisa treat?
A. Sarclisa is used with pomalidomide and dexamethasone to treat adults with relapsed or refractory multiple myeloma who have previously been treated with at least two therapies.
Q. What dosage forms are available?
A. Sarclisa is available in 100 mg/5 mL and 500 mg/25 mL vials for intravenous administration.
Q. What are common side effects of Sarclisa?
A. Common side effects include: neutropenia, infusion reactions, upper respiratory infections, diarrhea, and pneumonia.
Q. How should Sarclisa be stored?
A. Store vials at 2°C to 8°C (36°F to 46°F) in the original carton. Do not freeze or shake.
Q. Can Sarclisa be used during pregnancy or breastfeeding?
A. Sarclisa can cause fetal harm. Avoid use during pregnancy and breastfeeding. Effective contraception is recommended during treatment and for 5 months after the final dose.
Q. How can I access Sarclisa in India?
A. Contact GlobalRareMeds with the required documentation. We ensure genuine supply and compliant import handling for access to Sarclisa across India and beyond.
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
